Pharmaceutical

Takeda’s ADZYNMA gains EU approval for cTTP treatment

The European Commission (EC) has approved Takeda's ADZYNMA (recombinant ADAMTS13) for congenital thrombotic thrombocytopenic purpura (cTTP).

Aug 9, 2024 - 04:00
Takeda’s ADZYNMA gains EU approval for cTTP treatment
The European Commission (EC) has approved Takeda's ADZYNMA (recombinant ADAMTS13) for congenital thrombotic thrombocytopenic purpura (cTTP).
Read the original article

Tags:

Previous Article

Bavarian Nordic tops up US smallpox/mpox vaccine stockpile with $156.8m order

Next Article

Amneal’s CREXONT gains FDA approval for Parkinson’s treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Trametinib dimethyl sulfoxide by Novartis for Relapsed ...

Oct 25, 2023

New AI model boosts early osteoporosis diagnosis for ageing populations

New AI model boosts early osteoporosis diagnosis for ag...

Jul 30, 2024

Opinion: Current large language models will not fix health care. Here’s what could

Opinion: Current large language models will not fix hea...

Aug 25, 2023